The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy
Metrics: PDF 1350 views | HTML 1613 views | ?
Lin-Lin Cao1,*, Zhihong Yue1,*, Lianhua Liu1, Lin Pei1, Yue Yin1, Li Qin1, Jie Zhao1, Huixin Liu2, Hui Wang1 and Mei Jia1
1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing 100044, People’s Republic of China
2Research Office, Peking University People’s Hospital, Beijing 100044, People’s Republic of China
*These authors contributed equally to this work
Lin-Lin Cao, email: [email protected]
Mei Jia, email: [email protected]
Keywords: HDAC1, meta-analysis, gastrointestinal malignancy, clinical feature, overall survival
Received: December 21, 2016 Accepted: March 17, 2017 Published: April 05, 2017
Gastrointestinal malignancy is a severe public health threat worldwide, and survival for most types of gastrointestinal cancer is very poor. Therefore, finding better cancer biomarkers to diagnose gastrointestinal malignancy and predict patient survival is essential. HDAC1 has been reported to be closely associated with several types of cancer, but the precise role of HDAC1 in gastrointestinal cancer is not clear. Recently, quite a few studies have investigated the correlation between HDAC1 expression and clinical features or prognosis in multiple types of gastrointestinal malignancies, but the results were inconsistent. In this study, we systematically reviewed the association between HDAC1 and gastrointestinal malignancy using meta-analysis methods, and 28 eligible studies were analyzed. We found that the expression level of HDAC1 in gastrointestinal malignancies, especially in colorectal cancer (OR = 10.84, 95% CI = 5.33–22.07, P< 0.00001), was higher than that in noncancerous tissue, and HDAC1 expression was closely associated with some clinical features of gastrointestinal cancer patients, such as tumor stage (OR = 1.62, 95% CI = 1.28–2.05, P < 0.0001) and tumor grade (OR = 1.75, 95% CI = 1.03–2.95, P = 0.04). In addition, we also found that patients with low HDAC1 expression showed better overall survival than those with high HDAC1 expression in gastrointestinal malignancy, especially in gastric cancer (HR = 1.88, 95% CI = 1.14–3.12, P = 0.01). Our results strongly suggest that HDAC1 may serve as a good diagnostic and prognostic marker for gastrointestinal malignancy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.